Table 3.

Clinical trials of TNFα antagonists in AS

Reference	Agent	Protocol	Disease duration at entry (mean) years	Previous treatment	BASDAI 50 D/P, % patient	ASAS 20 D/P, % patient
[26]	INF	5 mg/kg, 12 weeks study [26], open-label extension 1 year [27], 2 years [28], and 3 years [29]	16.4 (placebo)	No DMARDs	53/9	73/27
[27]			14.9 (INF)
[28]
[29]
[30]	INF	5 mg/kg, 24 weeks study (ASSERT)	13.2 (placebo) 7.7 (INF)	Yes DMARDs	51/10.7	61.2/19.2
[31]	ETA	25 mg biweekly, 16 weeks, open-label extension 40 weeks	12 (placebo) 15 (ETA)	Yes DMARDs 38%
[32]	ETA	25 mg biweekly, 12 weeks Open-label, crossover up to 30 weeks for the initial placebo group and 24 weeks for the eta group	11 (placebo) 15 (ETA)	Yes, previous DMARDs, steroid Allow concomitant NSAIDs	57/6	78.6/25
[33]	ETA	25 mg biweekly, 24 weeks	10.5 (placebo) 10.1 (ETA)	43–44% concomitant DMARDs, steroid		59/28
[34]	ETA	25 mg biweekly, 12 weeks	9.7 (placebo) 15 (ETA)	Yes prior DMARDs, allow concomitant DMARDs, steroid, NSAIDs	71.1/25.6	60/23
[35]	ADA	40 mg every other week, 24 weeks, open-label up to 80 weeks (ATLAS)	10 (placebo) 11.3 (ADA)	Yes prior DMARDs Allow concomitant DMARDs, steroid, NSAIDs	45.2/15.9 (12 weeks) 42.3/15 (24 weeks)	58.2/20.6 (12 weeks) 51/19 (24 weeks)